Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Editorial

Current Pharmaceutical Interventions and Drug Design in the Management of Diabetes and Diabetic Complications

Author(s): Gopal L. Khatik, Ashok K. Datusalia and Manish Vyas

Volume 25, Issue 23, 2019

Page: [2509 - 2509] Pages: 1

DOI: 10.2174/138161282523190913113841

Next »
[1]
Usman B, Satija S, Sharma N, et al. Recent developments in alpha-glucosidase inhibitors for management of type-2 diabetes: An update. Curr Pharm Des 2019; 25(23): 2510-25.
[2]
Prabhakar PK, Sivakumar PM. Protein tyrosine phosphatase 1B inhibitors: A novel therapeutic strategy for the management of type 2 diabetes mellitus. Curr Pharm Des 2019; 25(23): 2526-39.
[3]
Ahsan W. The journey of thiazolidinediones as modulators of PPARs for the management of diabetes: A current perspective. Curr Pharm Des 2019; 25(23): 2540-54.
[4]
Taliyan R, Sarathlal KC, Kakoty V. Therapeutic approaches to Alzheimer’s type of dementia: A focus on FGF21 mediated neuroprotection. Curr Pharm Des 2019; 25(23): 2555-68.
[5]
Mishra V, Yadav N, Saraogi GK, Tambuwala MM, Giri N. Dendrimer based nanoarchitectures in diabetes management: An overview. Curr Pharm Des 2019; 25(23): 2569-83.
[6]
Kalvala AK, Khan I, Gundu C, Kumar A. An overview on ATP dependent and independent proteases including an anterograde to retrograde control on mitochondrial function: Focus on diabetes and diabetic complications. Curr Pharm Des 2019; 25(23): 2584-94.

© 2024 Bentham Science Publishers | Privacy Policy